Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
25,397,669
-
Shares change
-
-3,686,784
-
Total reported value, excl. options
-
$309,589,838
-
Value change
-
-$81,437,251
-
Put/Call ratio
-
1.78%
-
Number of buys
-
63
-
Number of sells
-
-46
-
Price
-
$12.19
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2021
137 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q2 2021.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25,397,669 shares
of 56,078,244 outstanding shares and own 45.29% of the company stock.
Largest 10 shareholders include Bellevue Group AG (3,463,000 shares), NEA Management Company, LLC (3,449,845 shares), RA CAPITAL MANAGEMENT, L.P. (2,589,904 shares), BlackRock Inc. (2,154,212 shares), BOXER CAPITAL, LLC (2,014,858 shares), Artal Group S.A. (1,646,517 shares), VANGUARD GROUP INC (1,560,459 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1,047,599 shares), FEDERATED HERMES, INC. (875,952 shares), and MORGAN STANLEY (600,964 shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.